Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)LeasesOther Gross PP&E AdjustmentsReceivables - Other
Ratios

Moleculin Biotech (MBRX) Accumulated Depreciation & Amortization (2016 - 2019)

Moleculin Biotech (MBRX) has 4 years of Accumulated Depreciation & Amortization data on record, last reported at $199000.0 in Q4 2019.

  • For Q4 2019, Accumulated Depreciation & Amortization rose 192.65% year-over-year to $199000.0; the TTM value through Dec 2019 reached $199000.0, up 192.65%, while the annual FY2019 figure was $199000.0, 192.65% up from the prior year.
  • Accumulated Depreciation & Amortization reached $199000.0 in Q4 2019 per MBRX's latest filing, up from $68000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $199000.0 in Q4 2019 and bottomed at $1000.0 in Q2 2016.
  • Average Accumulated Depreciation & Amortization over 4 years is $30000.0, with a median of $8000.0 recorded in 2017.
  • Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 700.0% in 2017, then surged 87.5% in 2018.
  • A 4-year view of Accumulated Depreciation & Amortization shows it stood at $6000.0 in 2016, then soared by 200.0% to $18000.0 in 2017, then skyrocketed by 277.78% to $68000.0 in 2018, then skyrocketed by 192.65% to $199000.0 in 2019.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $199000.0 in Q4 2019, $68000.0 in Q4 2018, and $27000.0 in Q3 2018.